By exercising their warrants ahead of schedule, this further confirms Aphira's commitment to accelerate Tetra's development work. I am pleased to report to shareholders that Tetra is in a solid financial position with over $4 million to continue advancing its strategic plan of becoming a leading bio-pharma organization focused on cannabis."